{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:57:42Z","timestamp":1783144662735,"version":"3.54.6"},"reference-count":100,"publisher":"Informa UK Limited","issue":"11","funder":[{"name":"not receive any funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2021,11,2]]},"DOI":"10.1080\/13543776.2021.1939308","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T05:44:37Z","timestamp":1622785477000},"page":"1059-1074","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Mucormycosis medications: a patent review"],"prefix":"10.1080","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-1040","authenticated-orcid":false,"given":"Mohd.","family":"Imran","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-3848","authenticated-orcid":false,"given":"Alshrari","family":"A.S.","sequence":"additional","affiliation":[{"name":"Department of Biological Science, Faculty of Science, Northern Border University, Arar, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Tauseef","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Chicago States University, Chicago, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah Alam","family":"Khan","sequence":"additional","affiliation":[{"name":"College of Pharmacy, National University of Science and Technology, Muscat, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaibu Abdullahi","family":"Hudu","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Parasitology, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-461X","authenticated-orcid":false,"family":"Abida","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12566"},{"key":"cit0002","volume-title":"StatPearls [Internet]","author":"Hern\u00e1ndez JL","year":"2020"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/bs.aambs.2019.10.003"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12466"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-009600"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.3390\/jof5010026"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.3390\/jof5010023"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-316430"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.07.011"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myx101"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-01751-4_45-1"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30312-3"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2016.52.1.2404002"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2020.101007"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2012.711741"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.3.556-569.2005"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.06.013"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-013-9629-0"},{"key":"cit0019","unstructured":"Fukuda H, Hayase T, Mizuguchi E, et al. N-substituted carbamoyloxyalkyl-azolium derivatives. US7459561B2. 2008."},{"key":"cit0020","unstructured":"Olin M Amphotericins, their salts and method of manufacture. GB795482A. 1958."},{"key":"cit0021","unstructured":"Bennett F, Ganguly AK, Girijavallabhan VM, et al. Tetrahydrofuran antifungals. US5661151A. 1997."},{"key":"cit0022","unstructured":"Acklin P, Lattmann R Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators. US6465504B1. 2002."},{"key":"cit0023","unstructured":"Ray SJ, Richardson K Triazole antifungal agents. US5567817A. 1996."},{"key":"cit0024","unstructured":"Liu L, New antifungal macrocyclic polyene compounds. CN112175029A. 2021"},{"key":"cit0025","unstructured":"Covel J, Shaw KJ, Trzoss M, et al. Heterocycle substituted pyridine derivative antifungal agents. WO2020247804A1. 2020."},{"key":"cit0026","unstructured":"Covel J, Shaw KJ, Trzoss M, et al. Heterocycle substituted pyridine derivative antifungal agents. WO2019113542A1. 2019."},{"key":"cit0027","unstructured":"Barbey S, Bougeret C, Briand JF, et al. 1,2,4-Thiadiazole derivatives antifungal compounds, compositions containing said compounds and the use thereof. WO2007012724A1. 2007."},{"key":"cit0028","unstructured":"Buchan ZA, Gustafson GD, Hoekstra WJ, et al. Metalloenzyme inhibitor compounds as fungicides. WO2015160665A1. 2015."},{"key":"cit0029","unstructured":"Buchan ZA, Gustafson GD, Hoekstra WJ, et al. Metalloenzyme inhibitor compounds as fungicides. WO2015160664A1. 2015."},{"key":"cit0030","unstructured":"Wasan EK, Wasan KM Stabilized formulation for oral administration of therapeutic agents and related methods. US8673866B2. 2014."},{"key":"cit0031","unstructured":"Wasan EK, Wasan KM Formulations for the oral administration of therapeutic agents and related methods. US8592382B2. 2013."},{"key":"cit0032","unstructured":"Betancourt A, Hnik P, Thibert R Solid oral formulations of amphotericin B. WO2020028508A1. 2020."},{"key":"cit0033","unstructured":"Bruno V, Ibrahim A, Watkins T Methods of treating or preventing mucormycosis. WO2020006438A1. 2020."},{"key":"cit0034","unstructured":"Chawla L, Tidmarsh G Methods of administering hepcidin. US20190240292A1. 2019."},{"key":"cit0035","unstructured":"Av-Gay Y, Greenberg D, Tal A Nitric oxide inhalation therapy for infants with bronchiolitis. US2020246573A1. 2020."},{"key":"cit0036","unstructured":"Dessen A, Hill KE, Klinkenberg G, et al. use of alginate oligomers to enhance the effects of antifungal agents. US2015126467A1. 2015."},{"key":"cit0037","unstructured":"Edwards JE, Ibrahim AS, Spellberg BJ Combi compositions for the treatment of mucormycosis. comprising iron chelator and antifungal agent. AU2007272781B2. 2012."},{"key":"cit0038","unstructured":"Burnie JP Treatment of fungal infection with polyene or beta glucan synthase inhibitor antifungals combined with anti HSP90 antibodies. EP1267925B1. 2007."},{"key":"cit0039","unstructured":"Clackson TP, Gilman MZ, Holt DA, et al. Materials and method for treating or preventing pathogenic fungal infection. US6258823B1. 2001."},{"key":"cit0040","unstructured":"Gray PW Chitinase materials and methods. US6372212B1. 2002."},{"key":"cit0041","unstructured":"Duncan V, O\u2019Neil D Use of cysteamine in treating infections caused by yeasts\/moulds. AU2015323566B2. 2018."},{"key":"cit0042","unstructured":"Catherine H, Gopal K, Leonore WL, et al. Particulate-stabilized injectable pharmaceutical compositions of posaconasol. BRPI0510417A. 2007."},{"key":"cit0043","unstructured":"Keith CT, Lehar J, Serbedzija GN, et al. Combinations for the treatment of fungal infections. WO2005082054A2. 2005."},{"key":"cit0044","unstructured":"Auspitz BA, Johansen LM, Serbedzija GN Combinations for the treatment of fungal infections. WO2005053613A2. 2005."},{"key":"cit0045","unstructured":"Wu H Pharmaceutical composition and applications thereof. CN104739834A. 2015."},{"key":"cit0046","unstructured":"Chevion M, Vinokur V Compositions and methods for treatment of iron overload. WO2019202584A1. 2019."},{"key":"cit0047","unstructured":"Auspitz BA, Keith C, Nichols MJ, et al. Combinations for the treatment of fungal infections. WO03066049A1. 2003."},{"key":"cit0048","unstructured":"Coates A, Hu Y Methods and compositions for treating microbial infection using pyrroloquinone US9789101B2. 2017."},{"key":"cit0049","unstructured":"Coates A, Hu Y A therapeutic agent for microbial infection comprising a combination of nordihydroguaiaretic acid and aminoglycoside. JP6282337B2. 2018."},{"key":"cit0050","unstructured":"Coates A, Hu Y Combination and use. US10335454B2. 2019."},{"key":"cit0051","unstructured":"Coates A, Hu Y Formulation. WO2017098274A1. 2017."},{"key":"cit0052","unstructured":"Draper M, Nelson ML Substituted tetracycline compounds as synergistic antifungal agents. WO2002072031A2. 2002."},{"key":"cit0053","unstructured":"Burnie JP Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti HSP90 antibodies. WO0176627A1. 2001."},{"key":"cit0054","unstructured":"Edwards JE, Fu Y, Ibrahim AS, et al. Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases. US8444985B2. 2013."},{"key":"cit0055","unstructured":"Edwards JE, Filler S, Fu Y, et al. Mammalian receptors as targets for antibody and active vaccination therapy against mold infections. US9259467B2. 2016."},{"key":"cit0056","unstructured":"Edwards JE, Filler S, Fu Y, et al. immunotherapy and diagnosis of mucormycosis using CotH. US9279002B2. 2016."},{"key":"cit0057","unstructured":"Brocchini S, Choi JW, Godwin A, et al. Complexes having adjuvant activity. EP1701741B1. 2008."},{"key":"cit0058","unstructured":"Brix L, Pedersen H, Sch\u00f8ller J Molecular vaccines for infectious disease. US10369204B2. 2019."},{"key":"cit0059","unstructured":"Cojocaru GS, Dassa L, Kliger Y, et al. VSTM5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases. US2016272707A1. 2016."},{"key":"cit0060","unstructured":"Laskavyj VN, Malakhova EA, Panferov VI Combined vaccine for rabbit visceral mycoses. RU2352355C1. 2009."},{"key":"cit0061","unstructured":"Alanio A, Dromer F, Janbon G, et al. Recombinant aspartyl protease antigen or antibody thereto for use in immunotherapy of fungal diseases. WO2017109028A1. 2017."},{"key":"cit0062","unstructured":"Zhang G, Zhang H Medical plants synergist having antifungal activity and drug tolerance of reversion azole antifungal agents. CN101032486B. 2011."},{"key":"cit0063","unstructured":"Divi SB, Medasani M Picrorhiza extract for prevention, elimination and treatment of infection diseases; United States Patent. US9603885B2. 2017."},{"key":"cit0064","unstructured":"Divi SB, Medasani M Picrorhiza extract for prevention, elimination and treatment of infection diseases. US9125921B2. 2015."},{"key":"cit0065","unstructured":"Armstrong ET Anti-infective mangrove extract against viruses, bacteria and fungi. US20120040033A1. 2012."},{"key":"cit0066","unstructured":"Divi SB, Medasani M Picrorhiza kurroa extract for prevention, elimination and treatment of DNA based viruses in humans and in biotech industry. US9433656B2. 2016."},{"key":"cit0067","unstructured":"Coates A, Hu Y Antimicrobial combinations and their use in the treatment of microbial infection. US2019111067A1. 2019."},{"key":"cit0068","unstructured":"Wenkang YW Chinese herbal medicine preparation for preventing and treating aquatic product animal mycoses, its preparation process and use. CN101011547A. 2007."},{"key":"cit0069","unstructured":"Chen H, Lu D, Tang X, et al. Chinese herbal medicine preparation for controlling fish hydromycosis and application thereof. CN109602873A. 2019."},{"key":"cit0070","unstructured":"Chen J, Shi D Chinese herba preparation for treating mucormycosis of Cyclemys trifasciata and preparation method of Chinese herbal preparation. CN104873863A. 2015."},{"key":"cit0071","unstructured":"Chen J, Shi D Feed for treating mucormycosis of Cyclemys trifasciata and preparation method of feed. CN104872438A. 2015."},{"key":"cit0072","unstructured":"Bloch I, Katz C Combination therapies including human chitinase (chit1) for the treatment of systemic fungal infection. WO2018078626A1. 2018."},{"key":"cit0073","unstructured":"O\u2019Neil D Use. US2016106689A1. 2016."},{"key":"cit0074","unstructured":"Lee PS, Stossel TP Use of gelsolin to treat infections. AU2011218617B2. 2014."},{"key":"cit0075","unstructured":"Cavanagh H Anti-fungal treatments. WO2006108215A1. 2006."},{"key":"cit0076","unstructured":"Koo S, Marty FM Volatile metabolite profiles for the diagnosis and treatment of mucorales fungi. US20190183887A1. 2019."},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0069-4"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-016-0255-4"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1185361"},{"key":"cit0080","unstructured":"Beswick MC, Coates A, Cramp SM, et al. use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms. WO2008142384A1. 2008."},{"key":"cit0081","unstructured":"Hurley TB, Peukert S, Wattanasin S Inhibitors of undecaprenyl pyrophosphate synthase. WO2008014311A2. 2008."},{"key":"cit0082","unstructured":"Hoekstra WJ, Yates CM Metalloenzyme inhibitor compounds. WO2013090210A1. 2013."},{"key":"cit0083","unstructured":"Hoekstra WJ, Yates CM Metalloenzyme inhibitor compounds. WO2014201161A1. 2014."},{"key":"cit0084","unstructured":"Br\u00fcnner N, Ingmer H, Vestergaard M Compounds for treatment of microbial infection. WO2020079051A1. 2020."},{"key":"cit0085","unstructured":"Chirkin E, Nantermet P, Roemer T, et al. Bifunctional antifungal agents and methods of treating fungal infection. WO2018035424A1. 2018."},{"key":"cit0086","unstructured":"Hoekstra WJ, Shaver SR, Yates CM Metalloenzyme inhibitor compounds. WO2017117393A1. 2017."},{"key":"cit0087","unstructured":"Hoekstra WJ, Rafferty SW, Schotzinger RJ Metalloenzyme inhibitor compounds. WO2013109998A1. 2013."},{"key":"cit0088","unstructured":"Bahadoor A, Castro AC, Chan LK, et al. Tetrazolones as inhibitors of fatty acid synthase. WO2011140190A1. 2011."},{"key":"cit0089","unstructured":"Bahadoor A, Castro AC, Chan LK, et al. Triazoles as inhibitors of fatty acid synthase. WO2011140296A1. 2011."},{"key":"cit0090","unstructured":"Hurley TB, Lee K, Peukert S, et al. Inhibitors of undecaprenyl pyrophosphate synthase. WO2008014307A2. 2008."},{"key":"cit0091","unstructured":"Del-Poeta M, Haranahalli K, Lazzarini C, et al. Anti-fungals compounds targeting the synthesis of fungal sphingolipids. WO2018232298A1. 2018."},{"key":"cit0092","unstructured":"Bhagwat SS, Jafri MA, Patel MV Efflux pump inhibitors. WO2011101710A1. 2011."},{"key":"cit0093","unstructured":"Balkovec JM, Borchardt A, James KD Antifungal agents. WO2016201283A1. 2016."},{"key":"cit0094","unstructured":"Draper M, Nelson ML Substituted tetracycline compounds as antifungal agents. WO2002072022A2. 2002."},{"key":"cit0095","unstructured":"Liu C, Liu CY, Yang S, et al. Boron containing compounds and their uses. WO2020123881A1. 2020."},{"key":"cit0096","unstructured":"Beck PH, Brown MB, Clark DE, et al. use of pyrroloquinoline compounds to kill clinically latent microorganisms. WO2007054693A1. 2007."},{"key":"cit0097","unstructured":"James KDJ, Laudeman CP, Malkar NB, et al. Antifungal agents and uses thereof. WO2012119065A2. 2012."},{"key":"cit0098","unstructured":"Bommer JC, Prestwich G, Testa C Use of tetrakis (n-alkylpyridinium) -porphyrin derivatives for killing microbes or preventing growth. WO2010014728A1. 2010."},{"key":"cit0099","unstructured":"Coates A, Cramp SM, Dyke HJ, et al. Antimicrobial compounds based upon 4-aminoquinoline. WO2008117079A1. 2008."},{"key":"cit0100","unstructured":"Hoekstra WJ, Rafferty SW, Schotzinger RJ Metalloenzyme inhibitor compounds. WO2011133875A2. 2011."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2021.1939308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T10:32:39Z","timestamp":1635330759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2021.1939308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":100,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,2]]}},"alternative-id":["10.1080\/13543776.2021.1939308"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2021.1939308","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}